ABSTRACT

Aim: To evaluate the frequency and clinical spectrum of dermatological manifestations of pegylated interferon alfa2a and ribavirin combination treatment in patients with chronic hepatitis C .

Methods: This six month prospective observational study was carried at tertiary care teaching hospital. 106 CHC patients of either gender, ≥12 years of age, who had no co morbidities and skin diseases, were enrolled in the study and treatment started with peg interferon and ribavirin. They were reviewed monthly, for six months, for skin manifestations, which were also assessed by skin specialist. Fraction of diverseskin side effects was assessed. Mean and standard deviation for continuous variables was noted. Relationship between Genderand cutaneous manifestationswas assessed. Statically significant p value (<0.05) was checked with the help of Chi square test.

Results: Among 106 CHC patients selected, 61% were women and 39% were men. Mean age of patients were 36.4±6.9 years. Alopecia was the most frequently encountered cutaneous lesions51%, due to the use of peg interferon and ribavirin therapy, followed by pruritus 24.5%, generalized pigmentation 23.3% and urticaria 19%. Entire research participants except one noticed skin problems. There is no any noteworthyconnection among skin problems due to treatment and sex of patient

Conclusion: Dermatological side effects during 6 months therapy with peg Interferon and ribavirin for HCV were very common and varied. Alopecia was the commonest cutaneous manifestation. Treatment was not stopped in any patient as the lesions were not severe.

Keywords: Chronic Hepatitis C . Peg Interferon. Ribavirin .Alopecia. Cutaneous manifestation